Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
20/04/201813h00GlobeNewswire Inc.Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual MeetingNASDAQ:SMMTSummit Therapeutics Inc
19/04/201813h00GlobeNewswire Inc.Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical TrialNASDAQ:SMMTSummit Therapeutics Inc
13/04/201815h08Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:SMMTSummit Therapeutics Inc
11/04/201822h48Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
11/04/201813h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Pr...NASDAQ:SMMTSummit Therapeutics Inc
09/04/201816h01GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018NASDAQ:SMMTSummit Therapeutics Inc
05/04/201813h00GlobeNewswire Inc.Summit Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
28/03/201813h00GlobeNewswire Inc.Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual MeetingNASDAQ:SMMTSummit Therapeutics Inc
27/03/201813h00GlobeNewswire Inc.Summit Therapeutics Announces Placement of £15.0 Million of Ordinary SharesNASDAQ:SMMTSummit Therapeutics Inc
14/03/201812h00GlobeNewswire Inc.Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical ConferenceNASDAQ:SMMTSummit Therapeutics Inc
13/03/201812h00GlobeNewswire Inc.Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea...NASDAQ:SMMTSummit Therapeutics Inc
07/03/201813h00GlobeNewswire Inc.Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional GroupNASDAQ:SMMTSummit Therapeutics Inc
26/02/201813h00GlobeNewswire Inc.Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMDNASDAQ:SMMTSummit Therapeutics Inc
23/02/201813h00GlobeNewswire Inc.Summit Therapeutics to Participate in 2018 BTIG Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
14/02/201821h03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMMTSummit Therapeutics Inc
09/02/201813h00GlobeNewswire Inc.Summit Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
30/01/201818h41Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMMTSummit Therapeutics Inc
25/01/201813h00GlobeNewswire Inc.Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical T...NASDAQ:SMMTSummit Therapeutics Inc
09/01/201813h00GlobeNewswire Inc.Summit Therapeutics to Present at the Biotech ShowcaseNASDAQ:SMMTSummit Therapeutics Inc
03/01/201819h47Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
23/12/201722h00GlobeNewswire Inc.Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva LtdNASDAQ:SMMTSummit Therapeutics Inc
06/12/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Pro...NASDAQ:SMMTSummit Therapeutics Inc
06/12/201708h00GlobeNewswire Inc.Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy ...NASDAQ:SMMTSummit Therapeutics Inc
04/12/201713h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 201...NASDAQ:SMMTSummit Therapeutics Inc
20/11/201713h00GlobeNewswire Inc.Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialNASDAQ:SMMTSummit Therapeutics Inc
09/11/201713h00GlobeNewswire Inc.Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ...NASDAQ:SMMTSummit Therapeutics Inc
06/11/201715h29GlobeNewswire Inc.Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
25/10/201715h00GlobeNewswire Inc.Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive DirectorsNASDAQ:SMMTSummit Therapeutics Inc
09/10/201713h00GlobeNewswire Inc.Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017...NASDAQ:SMMTSummit Therapeutics Inc
04/10/201713h00GlobeNewswire Inc.Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd ...NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT